Parallel phase I study of ixabepilone plus lapatinib and ixabepilone plus lapatinib plus capecitabine in subjects with HER2 [human epidermal growth factor receptor 2] positive locally advanced or metastatic breast cancer.

Trial Profile

Parallel phase I study of ixabepilone plus lapatinib and ixabepilone plus lapatinib plus capecitabine in subjects with HER2 [human epidermal growth factor receptor 2] positive locally advanced or metastatic breast cancer.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 11 Mar 2016

At a glance

  • Drugs Ixabepilone (Primary) ; Capecitabine; Lapatinib
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 01 Jul 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 15 Jun 2010 Planned end date changed from 1 Feb 2011 to 1 Sep 2010 as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top